Core Insights - Kangtuo Medical (688314.SH) reported a revenue of 251 million yuan for the first three quarters of 2025, representing a year-on-year growth of 4.57% [1] - The company's net profit attributable to shareholders remained stable at 76.72 million yuan, showing no change compared to the previous year [1] - The adjusted net profit was 71.61 million yuan, reflecting a year-on-year increase of 7.80% [1] - Basic earnings per share stood at 0.94 yuan [1]

Core Viewpoint - Kangtuo Medical (688314.SH) reported a total operating revenue of 251 million yuan for the first three quarters of 2025, representing a year-on-year increase of 4.57% [1] - The net profit attributable to shareholders of the parent company was 76.71 million yuan, remaining flat compared to the same period last year [1] - The basic earnings per share stood at 0.94 yuan [1] Summary by Category Financial Performance - Total operating revenue for the first three quarters reached 251 million yuan, with a year-on-year growth of 4.57% [1] - Net profit attributable to shareholders was 76.71 million yuan, unchanged from the previous year [1] - Basic earnings per share recorded at 0.94 yuan [1]

Core Viewpoint - Kangtuo Medical (688314.SH) reported a total operating revenue of 251 million yuan for the first three quarters of 2025, representing a year-on-year increase of 4.57% [1] - The net profit attributable to shareholders of the parent company was 76.71 million yuan, remaining flat compared to the same period last year [1] - The basic earnings per share stood at 0.94 yuan [1] Summary by Category Financial Performance - Total operating revenue for the first three quarters reached 251 million yuan, with a year-on-year growth of 4.57% [1] - Net profit attributable to shareholders was 76.71 million yuan, unchanged from the previous year [1] - Basic earnings per share were reported at 0.94 yuan [1]

证券代码：688314 证券简称：康拓医疗 公告编号：2025-039 西安康拓医疗技术股份有限公司 关于调整 2025 年限制性股票激励计划 授予价格的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、本次对 2025 年限制性股票激励计划授予价格进行调整的情况 西安康拓医疗技术股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日 召开第二届董事会第十九次会议，审议通过了《关于调整 2025 年限制性股票激 励计划授予价格的议案》，现将有关事项说明如下： 一、公司 2025 年限制性股票激励计划已履行的决策程序和信息披露情况 1、2025 年 4 月 28 日，公司召开第二届董事会第十六次会议，会议审议通 过了《关于公司<2025 年限制性股票激励计划（草案）>及其摘要的议案》《关于 <公司 2025 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东 会授权董事会办理公司 2025 年限制性股票激励计划相关事宜的议案》。 同日，公司召开第二届监事会第十二次会议，审议通过了《关于公司<20 ...

国浩律师（西安）事务所 关 于 西安康拓医疗技术股份有限公司 2025 年限制性股票激励计划调整相关事项 之 | | | 法 律 意 见 书 西安市雁塔区绿地中心 B 座 46 层 邮编：710065 The 46th Floor, Block B, Xi'an Greenland Center, Yanta District, Xi'an，710065,China 电话/Tel: +86 29 8819 9711 网址/Website: http://www.grandall.com.cn 2025 年 10 月 国浩律师(西安)事务所 法律意见书 国浩律师（西安）事务所 关于西安康拓医疗技术股份有限公司 2025 年限制性股票激励计划调整相关事项之 法律意见书 致：西安康拓医疗技术股份有限公司 国浩律师（西安）事务所（以下简称"本所"）接受西安康拓医疗技术股 份有限公司委托，担任其 2025 年限制性股票激励计划的特聘专项法律顾问。 本所律师根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股权激励管理办法》《上海证券交易所科创板股票上市规则》《科创板 上市公司信息披露业务指南第 4 号—— ...

Group 1 - The core viewpoint of the article highlights the financial performance of Kangtuo Medical in Q3 2025, showing a revenue increase and a positive net profit [1] - Kangtuo Medical reported a revenue of approximately 251 million yuan for the first three quarters of 2025, representing a year-on-year increase of 4.57% [1] - The net profit attributable to shareholders of the listed company was approximately 76.72 million yuan [1] Group 2 - As of the report date, Kangtuo Medical has a market capitalization of 2.9 billion yuan [2]

证券代码：688314 证券简称：康拓医疗 公告编号：2025-040 西安康拓医疗技术股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 04 日（星期二）14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 28 日（星期二）至 11 月 03 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥80,772,405.35, a decrease of 6.92% compared to the same period last year[4] - The total profit for the period was ¥24,365,076.68, reflecting a decline of 26.31% year-on-year[4] - The net profit attributable to shareholders was ¥21,716,516.65, down 22.22% from the previous year[4] - Total operating revenue for the first three quarters of 2025 reached ¥251,088,755.11, an increase of 4.1% compared to ¥240,117,907.83 in the same period of 2024[19] - Total operating costs for the first three quarters of 2025 were ¥156,565,067.29, up from ¥148,313,124.73 in 2024, reflecting a year-over-year increase of 5.5%[19] - Net profit for the first three quarters of 2025 was ¥75,906,135.43, slightly down from ¥76,006,339.62 in 2024, indicating a decrease of 0.1%[20] - The company reported a total profit of ¥89,724,401.40 for the first three quarters of 2025, compared to ¥92,332,439.71 in 2024, reflecting a decrease of 2.8%[20] Research and Development - Research and development expenses totaled ¥10,114,843.75, an increase of 23.61% compared to the same quarter last year, representing 12.52% of operating revenue[5] - Research and development expenses for the first three quarters of 2025 were ¥17,980,206.24, up from ¥16,399,769.03 in 2024, representing an increase of 9.7%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥790,933,245.95, an increase of 5.85% from the end of the previous year[5] - The equity attributable to shareholders increased by 8.29% year-on-year, reaching ¥688,268,864.98[5] - The company's total liabilities decreased to ¥100,587,268.91 in 2025 from ¥109,374,780.75 in 2024, a reduction of approximately 8.1%[17] - The total equity attributable to shareholders increased to ¥688,268,864.98 in 2025, compared to ¥635,577,490.21 in 2024, marking an increase of about 8.3%[17] Cash Flow - The net cash flow from operating activities was ¥23,893,689.92, down 29.17% year-on-year[5] - The company’s cash flow from operating activities for the first three quarters of 2025 showed a positive trend, although specific figures were not disclosed in the provided data[21] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 287,099,764.83, a slight decrease of 0.65% compared to CNY 288,963,805.42 in the same period of 2024[22] - The net cash flow from operating activities decreased to CNY 86,083,545.57, down 21.5% from CNY 109,654,732.43 year-on-year[22] - Cash inflow from investment activities totaled CNY 629,164,479.21, significantly increasing by 81.1% from CNY 347,020,186.10 in the previous year[23] - The net cash flow from investment activities was negative at CNY -193,046,531.01, worsening from CNY -151,796,237.78 in the same period last year[23] - Cash outflow from financing activities was CNY 33,577,694.13, compared to CNY 29,942,653.10 in the previous year, reflecting an increase of 8.7%[23] - The ending balance of cash and cash equivalents decreased to CNY 237,174,086.51, down 21.6% from CNY 302,407,498.71 at the end of the same period last year[23] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 5,879[11] - The largest shareholder, Hu Liren, holds 39,545,788 shares, representing 48.68% of total shares[11] Current Assets - Total current assets as of September 30, 2025, amount to ¥422,128,968.67, slightly up from ¥418,250,595.94 at the end of 2024[15] - Cash and cash equivalents decreased to ¥237,963,156.13 from ¥378,532,413.99[15] - Accounts receivable increased to ¥8,893,422.12 from ¥5,916,765.08, indicating a growth of 50.5%[15] - Inventory increased to ¥30,934,238.91 from ¥24,750,588.76, reflecting a rise of 24.9%[15] - Non-current assets total ¥368,804,277.28, up from ¥328,972,266.97[16] - Total assets increased to ¥790,933,245.95 from ¥747,222,862.91[16] - Current liabilities include accounts payable of ¥26,140,856.99, slightly up from ¥25,845,698.39[16] - The company has no short-term borrowings reported as of September 30, 2025[16] Other Information - The company reported a total of ¥195,239.57 in government subsidies recognized during the period, contributing positively to the financial results[7] - The company has not disclosed any significant new product developments or market expansion strategies in this report[10] - The company has not reported any net profit from mergers under common control for the current or previous periods, indicating no impact from such activities on the financial results[21] - The company experienced a negative impact of CNY -28,578.29 from exchange rate fluctuations on cash and cash equivalents[23]

Core Viewpoint - Kangtuo Medical announced a cash dividend of 0.20 yuan per share (including tax) for the first half of 2025, with key dates for the dividend distribution outlined [1] Summary by Categories Dividend Announcement - The cash dividend of 0.20 yuan per share will be distributed to shareholders [1] - The record date for the dividend is set for October 10, 2025 [1] - The ex-dividend date and the date of cash dividend payment are both scheduled for October 13, 2025 [1]

证券代码：688314 证券简称：康拓医疗 公告编号：2025-038 西安康拓医疗技术股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.20元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/10/10 | 2025/10/13 | 2025/10/13 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 9 月 16 日的2025年第二次临时股东会审议通 过。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本81,239,172股为基数，每股派发现金 红利0.20元（含税），共计派发现金红利16,247,834.40元。 三、 相关 ...